相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis
Jinlan Piao et al.
GYNECOLOGIC ONCOLOGY (2020)
Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option
M. Buechel et al.
ANNALS OF ONCOLOGY (2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N. Colombo et al.
ANNALS OF ONCOLOGY (2019)
Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicity
Daniel F. Pease et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Cochrane Systematic Review of Acetyl-L-Carnitine for the Treatment of Diabetic Polyneuropathy
Luiz C. Rolim et al.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2019)
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
S. Banerjee et al.
ANNALS OF ONCOLOGY (2018)
Randomized phase II study of the PDGFR antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
William P. McGuire et al.
BMC CANCER (2018)
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
M. K. Wilson et al.
ANNALS OF ONCOLOGY (2017)
Optimizing treatment in recurrent epithelial ovarian cancer
Giacomo Corrado et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin
A. Bergamini et al.
GYNECOLOGIC ONCOLOGY (2017)
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference
M. A. Bookman et al.
ANNALS OF ONCOLOGY (2017)
Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin
N. Blank et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
J. McGee et al.
ANNALS OF ONCOLOGY (2017)
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy
Alberto A. Gabizon et al.
DRUG RESISTANCE UPDATES (2016)
A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An JNRG Oncology/Gynecologic Oncology Group study
Lisa M. Landrum et al.
GYNECOLOGIC ONCOLOGY (2016)
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial
Sven Mahner et al.
EUROPEAN JOURNAL OF CANCER (2015)
The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
Jean-Marie Gibson et al.
ONCOLOGIST (2013)
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
L. Gladieff et al.
ANNALS OF ONCOLOGY (2012)
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Stan B. Kaye et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer
Nicoletta Colombo et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Squamous Cell Carcinoma of the Oral Cavity in Nonsmoking Women: A New and Unusual Complication of Chemotherapy for Recurrent Ovarian Cancer?
Timothy L. Cannon et al.
ONCOLOGIST (2012)
Pegylated Liposomal Doxorubicin and Gemcitabine in a Fixed Dose Rate Infusion for the Treatment of Patients With Poor Prognosis of Recurrent Ovarian Cancer A Phase Ib Study
Guillermo Crespo et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
Dimitrios Bafaloukos et al.
BMC MEDICINE (2010)
Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer
Ignace Vergote et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
Gabriella Ferrandina et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
David G. Mutch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
分享论文
